Saturday November 01, 2014




Help for CF

Comments

Saskatchewan patients with a rare form of cystic fibrosis will soon have access to a new oral medication. Beginning September 1, 2014, the province will provide coverage of Kalydeco to treat patients with a rare form of cystic fibrosis.

“This drug can help improve the quality of life and lung function for cystic fibrosis patients,” Health Minister Dustin Duncan said. “Our government is pleased to make this drug more accessible to the patients who need coverage to assist with the substantial cost of Kalydeco.”

Cystic fibrosis is a genetic disease affecting mainly children and young adults. It is a multi-system disease affecting mainly the lungs, as well as the digestive system.

“We applaud the Government of Saskatchewan for its compassionate action in making Kalydeco available to cystic fibrosis patients who need it,” Cystic Fibrosis Canada Vice President of Advocacy, Research and Health care Ken Chan said. “This funding decision will benefit the health and well-being of patients going on this medication.”

Saskatchewan is the third province among Pan-Canadian Pricing Alliance members to provide coverage, following Ontario and Alberta.  

In 2013, about 130 cystic fibrosis patients benefited from approved medications listed by the Saskatchewan Drug Plan, at a total cost to the province of about $1.75 million.

Cystic fibrosis patients seeking more information are encouraged to talk with their physicians, or call the Drug Plan and Extended Benefits Branch at 306-787-3317 in Regina or toll free at 1-800-667-7581.  Information about the Cystic Fibrosis Program is available online at www.health.gov.sk.ca/sail.


Comments

Comments


NOTE: To post a comment in the new commenting system you must have an account with at least one of the following services: Disqus, Facebook, Twitter, Yahoo, OpenID. You may then login using your account credentials for that service. If you do not already have an account you may register a new profile with Disqus by first clicking the "Post as" button and then the link: "Don't have one? Register a new profile".

The Yorkton This Week welcomes your opinions and comments. We do not allow personal attacks, offensive language or unsubstantiated allegations. We reserve the right to edit comments for length, style, legality and taste and reproduce them in print, electronic or otherwise. For further information, please contact the editor or publisher, or see our Terms and Conditions.

blog comments powered by Disqus


Quick Vote

Survey results are meant for general information only, and are not based on recognised statistical methods.


Markets





LOG IN



Lost your password?